Forxiga approved in Japan for chronic heart failure
Forxiga is the first SGLT2 inhibitor approved in Japan for chronic heart failure with reduced ejection fraction in adult patients with and without type-2 diabeteAstraZeneca’s Forxiga (dapagliflozin) has been approved in Japan for the treatment of patients with chronic heart failure (HF) who are receiving standard of care. HF is a life-threatening chronic disease that prevents the heart from pumping sufficient levels of blood around the body. It affects approximately 64 million people worldwide, at least half of whom have a reduced ejection fraction.[1-3] This occurs when the left